| Criterion Text | Inclusion/Exclusion | Disease | Biomarker | Prior Therapy | Criterion Rule |
| --- | --- | --- | --- | --- | --- |
| Metastatic melanoma or non-squamous NSCLC with untreated brain metastases | Inclusion | Melanoma, Non-squamous non-small cell lung cancer | - | - | (Disease = Melanoma) ∨ (Disease = Non-squamous non-small cell lung cancer) ∧ (Presence of untreated brain metastases) |
| Biopsy proven metastatic melanoma or non-squamous NSCLC with at least one untreated cerebral metastasis | Inclusion | Melanoma | None | None | (Disease = "melanoma" OR Disease = "non-squamous NSCLC") AND (Metastasis = "untreated" AND Size >= 5 mm AND Size < 20 mm AND Asymptomatic = true AND Requires local therapy = false) |
| Any number of previous treatments with the exception of previous inhibitors of programmed cell death 1 (PD-1), PD-L1, or programmed cell death 1 ligand 2 (PD-L2); other prior systemic therapies must have been administered at least 2 weeks before administration of pembrolizumab; the exception to this is ipilimumab, which must have been administered at least 4 weeks prior to the start of pembrolizumab; patients are not required to have had prior systemic therapy | Inclusion | None | None | Prior Therapy: PD-1, PD-L1, PD-L2, ipilimumab | - |
| A history of previously treated brain metastases is allowed, provided that at least 7 days have lapsed between radiation and initiation of pembrolizumab | Inclusion | Brain Metastases | None | Radiation or surgical resection | history of previously treated brain metastases ∧ (7 days have lapsed between radiation and initiation of pembrolizumab) |
| Any brain metastasis >= 20 mm or causing symptoms must be treated with local therapy (i.e. radiation or surgical resection, as clinically appropriate) prior to study enrollment | Inclusion | Brain Metastases | None | Radiation or surgical resection | (brain metastasis >= 20 mm) ∨ (causing symptoms) ∧ local therapy (radiation or surgical resection) |
| PD-L1 expression >= 1% in tumor tissue from any site | Inclusion | Non-small cell lung cancer (NSCLC) | PD-L1 | None | PD-L1 expression >= 1% in tumor tissue from any site |
| PD-L1 expression via central and/or local testing of PD-L1 Immunohistochemistry (IHC) by any Food and Drug Administration (FDA)-approved assay or an assay performed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory | Inclusion | Non-small cell lung cancer (NSCLC) | PD-L1 | None | PD-L1 expression via central and/or local testing of PD-L1 Immunohistochemistry (IHC) by any Food and Drug Administration (FDA)-approved assay or an assay performed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory |
| Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) | Inclusion | Anemia | Hemoglobin | Erythropoietin (EPO) | Criterion Text = "Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)" |
| AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases | Inclusion | Liver Metastases | - | - | AST ≤ 2.5 X ULN OR AST ≤ 5 X ULN OR (Liver Metastases AND ALT ≤ 2.5 X ULN) OR (Liver Metastases AND ALT ≤ 5 X ULN) |
| INR or PT ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants | Inclusion | None | None | Anticoagulant therapy | INR ≤ 1.5 X ULN OR (PT ≤ 1.5 X ULN AND (receiving anticoagulant therapy AND PT or PTT within therapeutic range)) |
| Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants | Inclusion | - | - | Anticoagulant therapy | aPTT or PTT <= 1.5 X ULN or (PT or PTT within therapeutic range of anticoagulants) |
| Symptomatic brain metastases; any neurologic symptoms present must have resolved with local therapy by the time of administration of study drug | Exclusion | Brain Metastases | - | Local Therapy | NOT (has_symptomatic_brain_metastases OR has_unresolved_neurologic_symptoms) |
| Patients with brain metastases for whom complete surgical resection is clinically appropriate | Exclusion | Brain Metastases | - | - | NOT (Brain Metastases AND Complete Surgical Resection Is Clinically Appropriate) |
| Patients with lung cancer with squamous histology | Exclusion | Lung cancer | - | - | NOT (Lung cancer with squamous histology) |
|  Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to start of treatment or has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent | Exclusion |  |  | Chemotherapy or targeted small molecule therapy within 2 weeks | - |
| Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy | Exclusion |  |  | Major surgery | Criterion Rule: (not (Major surgery)) |
| The use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed, and patients who previously required corticosteroids for symptom control must be off steroids for at least 1 week prior to treatment on day 1 of cycle 1; low-dose steroid use (=< 10 mg of prednisone or equivalent) as corticosteroid replacement therapy is allowed | Exclusion | None | None | Corticosteroid use | CorticosteroidUse(off) = true |
| Presence of leptomeningeal disease | Exclusion | Leptomeningeal disease |  |  | LeptomeningealDisease(true) → Ineligible |
| Has active autoimmune disease that has required systemic treatment in the past 2 years | Exclusion | Autoimmune disease | - | Systemic treatment with disease-modifying agents, corticosteroids, or immunosuppressive drugs | - |
| Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pembrolizumab breastfeeding must be discontinued if the mother is treated with pembrolizumab | Exclusion | None | None | Pembrolizumab | Pregnancy OR Breastfeeding |
|  Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis | Exclusion | Pneumonitis |  |  | HasPneumonitisHistoryOrCurrentPneumonitis() |
|  Has a known human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infection | Exclusion | HIV, HBV, HCV |  |  | HIV_status(known) ∧ HBV_status(known) ∧ HCV_status(known) |
| Inadequately controlled hypertension | Exclusion | Hypertension |  |  | Systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg |
| History of myocardial infarction or unstable angina within 3 months prior to cycle 1, day 1 | Exclusion | Myocardial infarction |  |  | formula: has-not-occurred(myocardial-infarction, 3 month) |
| History of stroke or transient ischemic attack within 3 months prior to cycle 1, day 1 | Exclusion | Stroke | - | - | NOT (stroke OR transient ischemic attack within 3 months) |
| Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to cycle 1, day 1 | Exclusion | Aortic aneurysm | - | - | NOT (vascular disease = "significant") AND (time from vascular disease diagnosis < 6 months) |
| Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation); any history of significant bleeding or thrombosis should be discussed with the study principal investigators (PIs) | Exclusion | Bleeding diathesis | - | - | NOT (Therapeutic Anticoagulation) AND (Bleeding Diathesis OR Clinically Significant Coagulopathy) |
| Warfarin is not permitted; prophylactic or therapeutic use of low molecular-weight heparin (e.g., enoxaparin), direct thrombin inhibitors or factor Xa inhibitors (direct or indirect) are permitted | Exclusion | None | None | Warfarin use | ¬(Warfarin) |
| Has a history of (non-infectious) pneumonitis that required steroids, current pneumonitis or evidence of interstitial lung disease | Exclusion | Pneumonitis | - | Steroids | HasHistoryOfPneumonitis(Steroids) ∧ HasCurrentPneumonitis ∧ HasEvidenceOfInterstitialLungDisease |
